West Pharmaceutical Services (WST) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
12 Mar, 2026Executive summary
Annual meeting scheduled for May 4, 2026, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and annual report before voting.
Voting matters and shareholder proposals
Election of eleven directors is on the agenda, with all nominees recommended by the board.
Advisory vote on named executive officer compensation (say-on-pay) is included.
Ratification of the independent registered public accounting firm for 2026 is proposed.
Shareholder proposal regarding adoption of an independent Board Chair policy is up for vote, with the board recommending against it.
Board of directors and corporate governance
Eleven director nominees are presented for election at the annual meeting.
Board recommends all nominees for election.
Latest events from West Pharmaceutical Services
- International growth, pipeline expansion, and diversification drive robust long-term outlook.WST
Bank of America Global Healthcare Conference 20248 Jul 2026 - 2025 sales and EPS guidance raised after strong Q1 results, despite restructuring and tariff impacts.WST
Q1 20258 Jul 2026 - Biologics and regulatory shifts drive robust growth and margin expansion in high-value packaging.WST
CJS Securities 25th Annual “New Ideas for the New Year” Investor Conference8 Jul 2026 - High-value product growth and market leadership drive strong financial outlook for 2026.WST
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Strong Q1 growth and effective cyber incident response support a positive long-term outlook.WST
Bank of America Global Healthcare Conference 202612 May 2026 - Director nominees reelected, executive pay approved, and independent chair proposal rejected.WST
AGM 20264 May 2026 - 2026 growth outlook is robust, with non-GLP-1 and regulatory tailwinds driving momentum.WST
2026 KeyBanc Capital Markets Healthcare Forum29 Apr 2026 - Raised full-year guidance after 21% sales growth and 47% adjusted EPS increase in Q1.WST
Q1 202623 Apr 2026 - Strong growth outlook driven by biologics, GLP-1s, and HVP transition, with margin expansion ahead.WST
Barclays 28th Annual Global Healthcare Conference27 Mar 2026